GlassScriptPhysician profile
Muhammad K Syed
NPI 1447440342
$3,620.59
in general payments reported to CMS, 2019-2025
34 companies · $89.76 in 2025
The $89.76 reported for 2025 was less than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $291 · 2020: $200 · 2021: $303 · 2022: $931 · 2023: $1,435 · 2024: $370 · 2025: $89.76.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,780 · Education: $115.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,780.08 |
| Education | $115.21 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $576.30 | 2021-2024 | Vraylar, Ubrelvy, Qulipta |
| Bayer Healthcare Pharmaceuticals INC. | $387.39 | 2022-2024 | |
| Glaxosmithkline, LLC. | $278.01 | 2019-2023 | Trelegy Ellipta, Arexvy, Shingrix |
| Boehringer Ingelheim Pharmaceuticals, INC. | $274.16 | 2021-2025 | Tradjenta, Jardiance, Stiolto Respimat |
| Novo Nordisk INC | $246.99 | 2019-2025 | Ozempic, Rybelsus |
| Astrazeneca Pharmaceuticals LP | $229.88 | 2019-2024 | Breztri |
| Sanofi-Aventis U.S. LLC | $217.25 | 2019-2023 | |
| Pfizer INC. | $182.56 | 2022-2024 | |
| Astellas Pharma US INC | $124.60 | 2022-2023 | Myrbetriq |
| Merck Sharp & Dohme LLC | $108.44 | 2019-2023 | Verquvo, Belsomra, Steglatro |
| Dexcom, INC. | $96.72 | 2021-2024 | Dexcom G6 Transmitter |
| Janssen Pharmaceuticals, INC | $87.87 | 2019-2022 | |
| Lilly USA, LLC | $87.07 | 2019-2023 | Mounjaro, Trulicity |
| Amgen INC. | $74.12 | 2020-2022 | |
| Abbott Laboratories | $62.74 | 2024-2025 | Freestyle Libre 3 |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sumitomo Pharma America, INC. | $61.81 | 2023 | Gemtesa |
| Axsome Therapeutics, INC. | $56.06 | 2022-2024 | Sunosi |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $51.72 | 2023 | Xifaxan |
| Sunovion Pharmaceuticals INC. | $51.49 | 2021-2022 | |
| Novartis Pharmaceuticals Corporation | $49.16 | 2022-2023 | |
| Idorsia Pharmaceuticals US INC | $46.71 | 2022-2023 | Quviviq |
| E.R. Squibb & Sons, L.L.C. | $34.78 | 2019-2022 | |
| Horizon Therapeutics Plc | $28.51 | 2020-2021 | |
| Indivior INC. | $27.40 | 2021 | |
| Eisai INC. | $24.45 | 2024 | |
| Almatica Pharma LLC | $21.07 | 2023 | Loreev Xr, Gralise |
| Esperion Therapeutics, INC. | $20.08 | 2023 | Nexletol |
| Exact Sciences Corporation | $18.64 | 2023 | Cologuard Collection Kit |
| Medtronic Vascular, INC. | $17.25 | 2020 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $16.54 | 2025 | Caplyta |
| Allergan, INC. | $16.30 | 2019 | |
| Boston Scientific Corporation | $15.72 | 2024 | Watchman Flx |
| Jazz Pharmaceuticals INC. | $14.53 | 2020 | |
| Lundbeck LLC | $14.27 | 2024 | Rexulti |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Muhammad Syed listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.